Testing ofatumumab for relapsing multiple sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests if ofatumumab can help people with relapsing multiple sclerosis (RMS) by measuring its effect on nerve damage markers in the blood. It aims to see if the drug is safe and effective for controlling relapses and slowing disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a diagnosis of relapsing multiple sclerosis (RMS) based on the 2017 McDonald criteria.
- Your disability level must be between 0 and 7 on the EDSS scale (able to walk with little to no help).
- You must be willing to have regular MRI scans and blood draws.
- You cannot be pregnant or planning to become pregnant.
- You must not have a history of progressive multifocal leukoencephalopathy (PML) or serious infections like active hepatitis B or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how ofatumumab (Kesimpta) affects the back of the eye (retina) and certain nerve proteins in the blood in people with relapsing multiple sclerosis. It may help doctors understand how well the medication is protecting the eyes and nerves.
This study follows adults with relapsing multiple sclerosis who are switching from ocrelizumab to ofatumumab (two similar MS medications) to see how their immune system proteins (immunoglobulins) change during the switch. It may help doctors understand if this change improves your immune health while treating MS.
This study tests an experimental drug called RO7121932 in people with multiple sclerosis. The goal is to see how safe it is and how the body processes it. It might help by offering a new way to manage the condition.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This study looks at how well different treatments, including bone marrow transplant, alemtuzumab, ocrelizumab, and ofatumumab, work for people with relapsing-remitting MS who have active disease. It will help doctors understand which therapy might slow disease progression best.
This early-stage trial tests a combination treatment—a CD20 antibody (which targets certain immune cells) paired with NK042 cell injection (a type of immune cell therapy)—for people with multiple sclerosis. The goal is to evaluate whether this combination is safe and may help slow disease progression.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.